The biopharmaceutical industry’s first quarter earnings season has been somewhat grim as the COVID-19 pandemic’s impacts on drug sales have become more apparent, but Amgen Inc. executives were relatively upbeat during the company’s Q1 call on 30 April based on business execution, the mix of products in its portfolio and the addition of Otezla (apremilast) late last year.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?